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This chapter aims to promote awareness by pro-
viding essential scientific elements about the 
risks associated with clinical oncology, with a 
particular focus on chemotherapy and 
radiotherapy.
Here as follows is the range of covered 
subjects:
• First, the epidemiologic and cultural context 
is addressed in order to understand the pecu-
liarity of oncology, a medical discipline in 
which the risk is directly related to the daily 
clinical practice, almost inseparable from the 
intervention that must be conducted, probably 
more than in any other branch of medicine.
• To increase specific knowledge, in a public 
health perspective, described herein is the 
epidemiology of the different adverse 
effects, listed according to their frequency of 
occurrence. The central topic of modern 
health organization in relation to the existing 
volume of activities, herein limited to sur-
gery, and the quality of health services, 
which can arouse debates of professional 
and organizational nature. Finally, safety 
practices, which were proven to be effective, 
and the strategies to implement them are 
also addressed.
18.1  Introduction
Developments in science and technology, 
together with the improved organization of health 
systems, have allowed remarkable progress in 
cancer diagnosis, care, and rehabilitation. In 
terms of assessment and management of the clin-
ical risk, however, considerable issues are raised 
by the continuously increasing frequency of the 
disease, the super specialization in care, the ele-
vated media attention, and the growing compe-
tence of patients and their associations.
Due to the complexity of their disease, cancer 
patients have access to different methodologies 
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and therapeutic strategies, all of which can be 




 – Hormonal therapy
 – Immunotherapy
 – Drug targeting
 – Gene therapy
 – Cell therapy
• Radiation therapy
 – External beam radiotherapy
 – Brachytherapy
 – IORT intraoperative radiotherapy
 – Radiometabolic therapy
Several therapeutic strategies can be adopted 
for treating oncology patients, including specific 
or combined/adjuvant approaches. Each strategy 
carries risks and adverse effects, which are not 
always acceptable, with the aim to achieve real 
benefits with the undertaken treatment.
The different, possible causes of these adverse 
events or errors, which can be frequent in certain 
situations, are discussed in this chapter.
Additionally, the chapter focuses on several 
strategies and organizational options aimed to 
minimize the risk and reduce therapeutic side 
effects, which can be negligible in some instances 
but very severe in others.
18.2  The Epidemiological Context
Tissue damage is unfortunately unavoidable dur-
ing radiation therapy and chemotherapy, as both 
approaches work by means of a mechanism of 
destruction of nucleic structures essential to can-
cer cells, in order to reduce cell multiplication. 
The setback is that most healthy cells are just as 
susceptible as cancer cells to the damaging 
effects of the treatments. Radiotherapy is based 
on ionizing radiations that must go through 
healthy tissues in order to reach the tumor. Even 
though new technologies are being developed, 
each more sophisticated and better able to pre-
cisely target the cancerous areas, the tissues sur-
rounding the tumor still tend to get damaged, but 
this is also due to the fact that the tissues sur-
rounding cancer cells are susceptible to micro-
scopic invasion by the malignant cells. 
Chemotherapy, as a pharmacological, systemic 
treatment, exerts its effects on the whole organ-
ism. Therefore, although in theory therapy could 
eliminate cancer cells, in practice it is often 
impossible as it becomes difficult to expose all 
cancer cells to adequate doses without damaging 
healthy tissues. Hence, the central issue of clini-
cal oncology consists in balancing cancer treat-
ment effects and the effects that therapies could 
have on the healthy tissues, reaching an equilib-
rium that, for a particular patient with a specific 
cancer type, the best possible therapeutic ratio 
could be obtained, meaning the best possible bal-
ance between the risk of damaging healthy cells 
versus killing cancer cells.
It is therefore accepted by the scientific com-
munity that collateral damage to healthy cells in 
oncology is often unavoidable. In other words, it 
has been accepted that during treatment with 
curative intent, adverse effects, including severe 
ones, can be expected to occur more than in other 
medical fields. Adverse events can occur during 
and after treatments with radiotherapy and with 
chemotherapy. Short-term or acute adverse 
effects occur during or shortly after treatment, 
and they usually last for a few days or up to 2 
weeks. Long-term or chronic adverse effects are 
more common in radiotherapy than in chemo-
therapy. They occur usually after treatment and 
sometimes even years later. These effects are 
usually irreversible and sometimes yield slowly 
progressive outcomes with severe consequences 
in terms of morbidity and, therefore, in terms of 
complaints and legal actions [1].
Approximately, one third of people may 
develop cancer during their lives. Today, about 
40% of cancer cases are curable. However, a 
number of patients can keep the disease under 
control for long periods of time though not 
achieving a complete recovery. As can be 
expected, at least half of them will die from their 
disease. The reason the numbers of simple com-
plaints and legal actions have dramatically 
increased in recent years lies in the high mortality 
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of the disease and the high toxicity rates of thera-
pies, on the one hand, and in the higher expecta-
tions of citizens regarding health services, on the 
other. This new perspective has been favored by 
higher cultural resources and by a higher aware-
ness of their own rights due to democratic 
progress.
The main areas of risk in clinical oncology 
include misdiagnosis (e.g., anticancer treatment 
delivered to patients without cancer, or to patients 
who had cancer in the past without disease recur-
rence, or for the wrong type of cancer), medica-
tion errors in preparation or administration, 
therapeutic toxicity, and negligence [1].
Two more categories can be added: delayed 
treatments, due to a delayed diagnosis, or delayed 
initiation or continuation of therapy, causing 
harm to the patient; over diagnosis risks in oncol-
ogy (e.g., PSA and TSH).
These are the most frequent categories of 
unfavorable outcomes afflicting patients. Some 
of the distinguishing characteristics of the spe-
cialty of oncology should be kept in mind. 
Oncology differs above all in the central role of 
the dedicated nurses and technicians who are 
specifically trained in the administration of 
sophisticated therapies. In radiotherapy in par-
ticular, a peculiar specificity exists, namely medi-
cal physicists who are called upon to run 
systematic quality checks of the linear accelera-
tors’ performance and to realize radiation treat-
ment plans. Furthermore, oncology has come to 
act according to multidisciplinary and multi- 
professional organizational models, following 
specific decisional protocols of clinical behavior.
18.3  Epidemiology of Adverse 
Effects
The most frequent adverse effects of cancer ther-
apies belong to the category of toxicity. In gen-
eral, radical treatments can result in very severe 
adverse effects in a small proportion of patients 
and in moderately severe adverse effects in a big-
ger proportion, even when conducted correctly 
and in accordance with to the appropriate clinical 
direction. The studies which have investigated 
the epidemiology of adverse effects mainly relate 
to chemotherapy.
In a cohort of 449 patients with cancer of the 
breast or lung or colon-rectum who underwent 
chemotherapy and followed up for a median time 
of 6 months, 86% reported at least one adverse 
effect during the study period and 27% an adverse 
effect of fourth degree, most often fatigue or dys-
pnea. Fatigue was the most frequent effect (85%), 
followed by diarrhea (74%), and constipation 
(74%). Prevalence and incidence rates of the 
adverse effects were similar among all types of 
cancer, and older age represented the only signifi-
cantly associated demographic factor [2].
In another cohort study, patients in treatment 
with antineoplastic drugs were followed up for 
2  years. Overall, 591 cases of adverse effects 
were reported, a 58.6% incidence rate. The prev-
alence of adverse effects was recorded among 
women (constituting 73% of the cohort). Of the 
patients with adverse effects, 50.2% requested a 
treatment, 12.9% were deemed severe cases, 
87% moderate, and 51% unpredictable [3].
An important further study was conducted on 
458 oncologic patients followed up for 8 months, 
investigating hospital stay. Among the unplanned 
hospital admissions, 13% were caused by a phar-
macological event, 13% by an adverse drug reac-
tion, and 2% by a major interaction between 
different drugs. In conclusion, one in 10 
unplanned hospital admissions of cancer patients 
was caused by a pharmacological effect [4].
It is estimated that between half and two thirds 
of new cancer cases receive treatment plans that 
include radiotherapy. Seventy-five percent of 
them are aimed to cure the patients. Radiotherapy- 
related adverse effects are the most frequent and 
they are described below.
Prevalence of depression among cancer 
patients is extremely variable, ranging from 0% 
to 60% in different case studies, according to 
study criteria, methodology, and populations. 
Depression is associated in particular with can-
cers of the oro-pharynx, lung, breast, brain, and 
pancreas, but rarely with gynecologic tumors and 
colorectal cancers. Since comorbidity and treat-
ment regimen are combined, in particular, with 
chemotherapy, it is often difficult to evaluate the 
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direct effect of radiotherapy on depression as 
well as on several other symptoms.
Patients often indicate fatigue as the most dis-
turbing adverse effect of radiotherapy, more than 
pain, nausea, and vomit. Fatigue correlated with 
radiotherapy occurs acutely in 80% of patients 
and chronically in 30% of patients. For this rea-
son, patients should be evaluated for this symp-
tom at regular intervals.
Dermatitis caused by radiation is a common 
adverse effect of radiotherapy, often complicat-
ing treatment of breast, prostate, perineum, and 
head and neck cancers. It is, however, difficult to 
evaluate the real burden of the phenomenon as 
clinical practice in this field is biased by unreli-
able and contradictory evidence. Early reactions 
include skin rash and dry and humid exfoliation, 
while delayed events include pigmentation 
changes, telangiectasias, hair loss, atrophy, and 
ulcerations.
Concerning vascular diseases due to radio-
therapy, a well-known adverse effect occurs 
mostly in Hodgkin lymphoma patients, and in 
lower numbers, in breast and lung cancer patients. 
It is estimated that the relative risk of cardiovas-
cular events after mediastinal radiation ranges 
from 2.2% to 7.2% for Hodgkin lymphoma cases 
and from 1% to 2.2% for cancer of the left breast.
Concerning lung effects, pneumonia due to 
radiation occurs in 5.15% of patients undergoing 
radiation for mediastinal cancers and breast and 
lung cancers. The risk is directly associated with 
the volume of the irradiated lung, intensity of 
radiation, and any concurrent chemotherapy. 
Toxicity of the digestive tract due to damage to 
the salivary glands is common in the radiation of 
the head and neck, especially in the case of con-
current chemotherapy. Esophagitis is also a com-
mon, early adverse effect whose frequency grows 
with the increasing of radioactive doses and in 
the presence of concurrent chemotherapy. Acute 
enteritis after radiotherapy is usually a self- 
limiting process by means of a correction to the 
diet and the administration of anti-diarrheal med-
ications. Usually, the symptoms start 3 months 
after the end of radiotherapy and can last indefi-
nitely. Another frequent symptom is the emesis 
induced by radiotherapy. The main risk factors 
include the completion of chemotherapy before 
radiation of the upper abdomen and the width of 
the irradiated areas. Patients who receive total- 
body radiations are at higher risk. Acute bladder 
infection, including the most severe hemorrhagic 
cystitis, is a less common effect of radiotherapy, 
and the risk is augmented by concurrent 
chemotherapy.
Sexual dysfunctions, including impotence, are 
common after radiotherapy for cancers of the 
prostate and, to a lesser extent, of the colon- 
rectum. They are primarily a concern for older 
patients, who show a higher frequency of prostate 
cancer diagnosis. Erection dysfunction is more 
common with brachytherapy and with external 
radiotherapy. Among women, sexual dysfunc-
tions are more common after radiotherapy for 
cervical and endometrial cancers. The adverse 
effects include a lower sex drive, vaginal dryness, 
and general sexual dissatisfaction.
18.4  Medication Errors 
in Oncology Practice
The publication of the report “To err is human” 
by the Institute of Medicine of Washington 
(IOM) in 1999 has led to a radical change in 
healthcare organizations with regard to the 
understanding of the phenomenon of medical 
error. In oncology, the current definition of med-
ication error, i.e., any “preventable event that 
may cause or lead to inappropriate medication 
use or patient harm while the medication is in 
the control of the healthcare professional, 
patient, or consumer,” is provided by the 
National Coordinating Council for Medical 
Error Reporting and Prevention.
A recent review of the literature from 1980 to 
2017 has shown that medical errors in chemo-
therapy occur at a frequency ranging from 1 to 4 
cases per 1000 prescriptions, concerning at least 
1–3% of patients and appearing in all phases of 
the cure process [5]. The definition of medication 
error applies to all areas of medicine but can have 
different implications depending on the complex-
ity of the discipline and the magnitude of the 
potential damage it can cause.
A. Marcolongo et al.
257
Cancer care is going through a revolutionary 
period both in the diagnostic and the therapeutic 
fields. At the same time, the substantial increase 
in scientific data is making the system increas-
ingly complex and constitutes a challenge for 
health professionals [6]. For example, the current 
rate of new therapeutic indications in hematology- 
oncology is about one per week, preventing the 
general medical oncologist from keeping up.
In oncology, several factors may expose 
patients to increased risk that can result in seri-
ous adverse effects (AEs) [5]. The greater vul-
nerability of cancer patients may be due to the 
fragility induced by the disease itself, to the nar-
row therapeutic index of many anticancer agents, 
or to the use of innovative therapies of which 
potential side effects and their management are 
not fully known. In addition, cancer care is often 
provided by inter-professional teams that need to 
be perfectly in tune when it comes to communi-
cation [7].
Quite surprisingly, although oncologists pay 
high attention to treatment-related toxicities of 
anticancer agents, oncology as a discipline lags 
behind other areas of medicine in focusing on 
understanding the nature of medication errors 
and the extent of their effects. Of note, only a few 
studies have analyzed the incidence and conse-
quences of medication errors in oncology [5, 8].
In December of 1994, a tragedy occurred that 
turned the spotlight on to the need to work sys-
tematically to ensure and strengthen safety mea-
sures in the administration of anticancer therapies. 
The incident occurred at the Dana-Farber Cancer 
Institute in Boston, a Harvard teaching hospital 
and a prestigious US institution, and caused the 
death of a young health journalist, Betsy 
A. Lehman, who died of a massive overdose of 
chemotherapy for breast cancer. A similar event 
occurred 2 days apart and caused permanent 
heart damage in a patient cared for by the same 
medical team. Both patients were treated with 
autologous stem-cell transplant, in the context of 
an experimental protocol that included high 
doses of cyclophosphamide. However, because 
of misinterpretation of the study protocol and 
subsequent miscalculated dosage, they received 
about four times the intended dose. The error was 
missed by other doctors, nurses, and pharmacists, 
including some senior members of the team.
Further attention was drawn to the importance 
of safe administration and management of che-
motherapy after another lethal event occurred in 
December of 2015, two decades after the death of 
Betsy Leman. The death of a 49-year-old man 
caused again by an unintended chemotherapy 
overdose catalyzed a call to action for healthcare 
systems to recognize and to implement safety 
principles and practices to prevent patient harm. 
Increased awareness and sensitivity regarding the 
risk of errors related to anti-tumor treatments 
and, in particular, to chemotherapy, has led the 
American Society of Clinical Oncology (ASCO) 
and the Oncology Nursing Society (ONS) to set 
standards to minimize treatment-related risks. 
The most updated version of the standards was 
published in 2016 and focused on four main 
points [9]:
• The environment and routine procedures
• Treatment planning and patient education 
before the start of treatment
• Specific standards for ordering, preparing 
(including labeling), and administering treat-
ment (chemotherapy)
• Monitoring adherence to, and toxicity from, 
chemotherapy to promote safety both while on 
treatment and subsequently
In particular, great attention is paid to the defi-
nition of the healthcare setting that includes the 
policy to ensure the relevant qualifications of the 
various professional figures involved in the 
order, preparation, and administration of the 
treatments.
Special emphasis is placed on training pro-
grams, on participation in basic life support 
courses by the clinical staff, and on information 
that must be reported in the medical record and 
verified before treatment (e.g., diagnosis, stage of 
illness, clinical history, physical examination, 
history of allergies, level of information shared 
with and understood by the patient and/or care-
givers, description of the treatment plan). In addi-
tion, the healthcare setting includes a policy on 
documents that standardizes the process for 
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obtaining treatment consent and valid proof of 
consent. Patients must be sufficiently informed 
about the treatment plan, the potential side 
effects, the management of adverse events, the 
handling of medicines at home, the follow-up 
visits, and the procedures they may be subjected 
to for monitoring during the therapy. Furthermore, 
patients must be provided with contact informa-
tion in case of need.
Regarding therapeutic orders, it is recom-
mended that they be signed by hand or electroni-
cally. Verbal orders are not allowed, with the 
exception of those for holding or stopping ther-
apy. New orders or changes to orders (e.g., dose 
adjustments) must be documented in the medical 
record. It is important that a chemotherapy order 
be extremely detailed and include the following 
information: the patient’s name, a second patient 
identifier, the date of the prescription order is 
written, the regimen or protocol identifier (name 
and number), the cycle number and day, all medi-
cations listed using full, generic names, the drug 
dose (to be written following the standards 
regarding abbreviations, trailing zeros, and lead-
ing zeros), the dose calculation, the date of 
administration, the route of administration, the 
presence of allergies, any supportive care treat-
ments appropriate for the regimens (e.g., premed-
ications, hydration, growth factors), parameters 
that would require holding or modifying the dose 
(e.g., laboratory tests, patient clinical status), the 
sequencing of drug administration, and the rate 
of drug administration. Special recommendations 
are given for prescriptions of oral chemotherapy.
The standards also include requirements for 
the preparation of chemotherapy which must be 
entrusted to licensed pharmacists, pharmacy 
technicians, physicians, or nurses with specific 
skills acquired as a result of specific education 
and training programs. Before preparation, a sec-
ond person has the task of independently verify-
ing the patient’s identifiers, the name of the drug, 
the dose, the route of administration, the rate of 
administration, the calculation of the dose, the 
treatment cycle, and the cycle day.
Upon preparation, one of the two operators 
must verify the drug vial(s), the concentration, 
the drug volume or weight, the diluent type and 
volume, and the administration fluid type, vol-
ume, and tubing.
Before each chemotherapy administration, at 
least two practitioners have to verify eight essen-
tial elements: the drug name, the drug dose, the 
infusion volume, the rate of administration, the 
route of administration, the expiration dates and/
or times, the physical integrity of the drugs, the 
rate set on the infusion pump.
Chemotherapy drugs—and ideally any drug 
used to treat cancer patients—must be labeled 
immediately upon preparation, including the fol-
lowing details [10]: patient’s name, a second 
patient identifier, full generic drug name, drug 
dose, drug administration route, total volume 
required to administer the drug, date the medica-
tion is to be administered, expiration dates and/or 
times, sequencing of drug administration and 
total number of products to be given when medi-
cation is provided in fractionated doses (e.g., one 
of five, two of two), and a warning about storage 
and handling.
Before the administration, the practitioner 
administering the treatment has to confirm it with 
the patient, reporting at least the following infor-
mation: drug name, infusion time, route of 
administration, and any infusion-related symp-
toms they should report. At least two individuals, 
in the presence of the patient, must verify the 
patient identification using at least two identifi-
ers. Documentation of chemotherapy administra-
tion must report the verification of the 
aforementioned eight elements that had to be 
checked before the administration (see above). 
Procedures to manage extravasation must be 
defined and must follow the most up-to-date 
guidelines. The antidote sets must be accessible 
within the appropriate timeframe. After the 
administration of the treatment, appropriate pro-
cedures must be adopted to monitor adherence, 
toxicity, and possible complications.
Some studies have analyzed the different 
clinical and management settings in which the 
medication errors were reported. Interestingly, 
most them were intercepted and corrected before 
they reached the patient [11–14]. Pharmacists or 
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nurses usually detected order-writing errors and 
informed clinicians, thus preventing harm to the 
patient. Therefore, no harm occurred as a result 
of error, in part thanks to the diligence of the 
staff and the special alertness of the team in 
questioning any unclear or ambiguous orders. 
This proactive approach allows the team to fre-
quently intercept errors before they cause seri-
ous AEs. In addition, it produces cultural changes 
among health professionals, consequently 
improving medication prescription processes 
(e.g., development and adoption of specific com-
puterized and noncomputerized order tem-
plates). In contrast, behaviors such as the hiding 
of errors or the sanctioning attitudes are an 
obstacle to the creation of a culture of patient 
safety among health professionals. Of note, hos-
pital-based or center-based incident reporting 
systems have often performed better than nation-
wide systems, in which the problem of underre-
porting is more common [15, 16].
18.5  Safety Practices 
and Implementation 
Strategy in Clinical Oncology
Different strategies have been proposed in order 
to reduce the risk of medication errors during 
cancer care or to mitigate their effects or harm to 
the patient (Table  18.1). Therapeutic orders 
should be drawn up from standardized and con-
tinuously monitored dictionaries. By using com-
puter technology, errors stemming from a 
misunderstanding of handwriting can be avoided. 
In the literature, there are some recommendations 
that mainly concern the way in which to report 
orders related to the prescription of chemother-
apy. In particular, some information should 
always be present in each order report, including 
patient data such as name, height, weight, and 
body surface area, and treatment characteristics 
such as route of administration, timing, and dose. 
Furthermore, specific checklists that include 
Table 18.1 Strategic measures to improve safe management of anticancer medicationa
Strategic areas Examples of intervention measures
Training •  All health professionals involved in treating cancer patients (i.e., physicians, pharmacists, 
nurses, technicians) must have the necessary knowledge and skillset to perform their 
functions.
•  Continuous education programs must be aimed at all staff members.
•  Periodic audits must be implemented for accreditation by authorized independent 
organizations.
Resources • Staff and technological resources must be commensurate with the volume of work.
• High pressure placed upon care staff must be avoided.
•  Information and communication technology-based integrated system focused on the 
management of cancer patients has to be part of the hospital infrastructures.
Operating 
procedures
•  The healthcare setting must have in place standard operating procedures which include 
strategies for preventing errors.
•  The operating procedures must contain clear definitions of the processes for prescribing, 
pharmaceutical reviewing, preparing, dispensing, administering, and monitoring anticancer 
therapy.
• Responsibilities of each member of the staff must be clearly indicated in each process.
•  The Center Cancer must have up-to-date dictionaries with evidence-based treatment 
protocols, clearly and unambiguously written, and accessible to all health professionals 




The involvement of the patient and one or more caregivers is encouraged in order to facilitate the 





• Standardization of treatment orders.
•  The use of a computerized physician order entry (CPOE) system integrated into the medical 
records, equipped with a clinical decision support system (CDSS) that allows to minimize 
prescribing errors (e.g., dose calculation alerts, adjustments according to clinical situations, 
allergies, maximum doses).
(continued)
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safety parameters to be evaluated before the pre-
scription should always be available. Examples 
of such checklists are forms with information on 
white blood cell counts, creatinine clearance, 
liver function indices, and drug interactions, 
among others.
It should be acknowledged that computer 
technology does not eliminate the risk of errors. 
Although Computerized Physician Order Entry 
(CPOE) systems and Clinical Decision Support 
Systems (CDSS) may limit some specific errors 
linked to incorrect order entry, many order entry 
alerts can be ignored or manually bypassed by 
physicians.
Prescription errors can be sensibly reduced by 
55–80% by a CPOE system with the aid of a 
CDSS [17]. The introduction of computerized 
information systems in clinical practice and the 
use of medical records have been reported to 
have positive effects on the reduction of clinical 
risk, not only in relation to the cycle of medica-
tion (i.e., planning of treatment, prescription, 
preparation, administration, follow-up) but also 
for diagnostic and therapeutic evaluation in 
general.
The importance of documenting the occur-
rence of errors is independent of the extent of the 
damage caused to the patient or even whether any 
damage has been caused.
It is well known that underreporting of errors 
is widespread; errors that cause less serious dam-
age often go untracked. However, the importance 
of providing information on near-miss or lesser 
injury events is increasingly clear. Policies that 
start from metrics and reporting are essential for 
improvement and the appropriate use of data is 
extremely useful when implementing manage-
ment practices that target-specific risks.
Barriers to compliance with reporting include 
low staff awareness, cumbersome interfaces for 
documenting and sharing data among healthcare 
professionals, the perception of wasted time and 
uselessness, or fear of repercussions in the form 
of punitive measures.
On the other hand, strategies for improvement 
include simplification, standardization, and use 
of information technology.
Patient safety must not be limited hierarchies. 
Everyone must be involved in proactive error pre-
vention. The physician, nurse, and pharmacist 
should all double-check therapeutic prescriptions 
[5, 18]. Patients, in turn, must be fully informed 
about the characteristics of the therapy and its 
administration. Everyone must feel encouraged 
Table 18.1 (continued)





•  The staff of the pharmacy must follow standard guidelines or protocols related to the 
composition, reconstitution, dilution, stability, labeling of each drug used at the site.
•  Anticancer therapy must be prepared by the pharmacy staff in a safety cabinet, which can be 
automated or not, for one patient at a time, and each drug must be prepared individually.
•  Preparation of anticancer therapy should be completed by the pharmacy staff in such a way 
that no further preparation is required by the health professional responsible for administering 
the treatment (i.e., nurses).
•  A standardized labeling method must be used for ensuring easy identification of patient, 
medication, route, and dose. Labels must be printed (not handwritten).
•  The components of intravenous mixtures of cancer drugs must be verified using bar codes or a 
similar system. The preparation phase of cytotoxic drugs should be centrally managed within 




• Anticancer therapy must be administered by a qualified member of nursing staff.
•  Before each drug administration, patient ID must be verified by the nurse in the presence of 
the patient, using at least two identifiers.
•  In addition, an expert nurse must confirm the treatment with the patient. Drug name, infusion 
time, route of administration, and infusion-related symptoms must be reported, establishing 
any symptoms the patient must promptly report.
Monitoring 
process
After anticancer drug administration, patients must be monitored for adherence, toxicity, and 
complications.
aMany of these statements are also appropriate for radiation therapy.
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to express any doubts. Each must share their 
work with the others; this is the key to success in 
preventing a large proportion of potential errors.
18.6  Radiotherapy
Radiotherapy (RT) is one of the major treatment 
options in cancer management and “it is widely 
known to be one of the safest areas of modern 
medicine, yet, for some, this essential treatment 
can bring harm, personal tragedy and even death” 
(Sir Liam Donaldson).
It is estimated that between one half and two 
thirds of new cancer cases receive RT [19], which 
is used with curative intent in 75% of the cases 
that receive it. RT is a highly effective treatment 
option for palliation and symptom control; how-
ever, its adverse effects are quite common.
RT has distinctive risk features owing to the 
invasiveness of the irradiating techniques used 
and to the seriousness of neoplastic disease [20]. 
The RT process is complex and makes use of 
highly specialized technical equipment. The 
technical advancement has played a decisive role 
for precision in treatment delivery, creating 
highly conformal dose distribution with steep 
dose gradients [21]. Whatever the changes might 
have been, the objective remains the same: to 
eradicate tumors and to eliminate all cells in the 
regions at risk with minimized normal tissue tox-
icity [22]. The radiation treatment process is rep-
resented can be broken down into a sequence of 
steps. A high level of accuracy is needed at every 
step for maximum tumor control with minimal 
risk to normal tissue, defined as Organ at Risk 
(OAR) [23] (Fig. 18.1).
Over the last two decades, numerous studies 
have reported an association between dosimetric 
parameters and normal tissue outcomes. In 2007, 
a joint task force of physicists and physicians was 
formed with the support of the American Society 
for Therapeutic Radiology and Oncology 
(ASTRO) and the American Association of 
Physicists in Medicine (AAPM) to summarize in 
the QUANTEC the available data in a format use-
ful to clinicians and to update and refine the esti-
mates provided [24, 25]. Recently, PENTEC 
(Pediatric Normal Tissue Effects in the Clinic) 
has tried to explore and define normal tissue tol-
erance in developing children as a function of 
dose and volume of radiation, type and schedul-
ing of chemotherapy, and surgery. This informa-
tion can ideally be used to inform radiation 
oncologists, patients, and parents of the risks and 
benefits of multimodality therapy involving radi-
ation therapy, to define radiation dose constraints 
for treatment planning, and to propose new 
research directions [26].
In general, RT-related symptoms depend on 
the site, volume irradiated, technique, total dose, 
dose fractionation, age of patient, concurrent 
therapy, and biology of involved tissue. RT 
adverse effects are classically divided into acute 
adverse effects (i.e., arising during the treatment 
and lasting for about 3 months) and late ones 
(i.e., arising 6 months after treatment). RTOG/
EORTC hoped to standardize the way of report-
ing late effects on both sides of the Atlantic [27]. 
This has been succeeded by the CTCAE scale 
(Common Toxicity Criteria for Adverse Events), 
whose most prominent features are the merging 
of early and late effects criteria into a single uni-
form document and the development of criteria 
applicable to all treatment methods (e.g., chemo-
therapy, RT, surgery, new biotechnological 
drugs) [28]. RT-related symptoms can be divided 
into general symptoms associated with the pro-
cedure or disease and specific symptoms related 
to the site of irradiation. Among the former, 
patients often indicate fatigue as the most dis-
turbing adverse effect of radiotherapy, ahead of 
pain, nausea, and vomit. Fatigue correlated with 
radiotherapy occurs acutely in 80% of patients 
and chronically in 30% of patients. For this rea-
son, patients should be evaluated for this symp-
tom at regular intervals. The prevalence of 
depression among cancer patients is extremely 
variable, ranging from 0% to 60% in the differ-
ent case studies, depending on study criteria, 
methodology, and populations. Depression is 
associated particularly with cancers of the oro-
pharynx, lung, breast, brain, and pancreas, and 
rarely with gynecologic tumors and colorectal 
cancers. Since comorbidity and treatment regi-
mens are usually combined with chemotherapy, 
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it is often difficult to evaluate the direct effect of 
radiotherapy on depression as well as several 
other symptoms [29].
Specific symptoms relating to the irradiation 
of specific regions involve several organs. Here, 
we summarize only the main ones.
Acute and late effects of RT on the central ner-
vous system are common and represent a signifi-
cant source of morbidity. In particular, patients 
with tumor-related neurocognitive dysfunction 
may exhibit exacerbated deficits after RT [30].
Dermatitis caused by radiation is a common 
adverse effect of radiotherapy, often complicat-
ing treatment of breast, prostate, perineum, and 
head and neck cancers. It is, however, difficult to 
evaluate the real burden of the phenomenon as 
clinical practice in this field is biased by unreli-
able and contradictory evidence [31]. Early reac-
tions include skin rash, and dry and humid 
exfoliation, while delayed events include 
 pigmentation changes, telangiectasias, hair loss, 
atrophy, and ulcerations.
With regard to vascular diseases due to radio-
therapy, patients who received left-sided radio-
therapy as compared with those receiving 
right-sided radiotherapy experienced increased 
risks of developing coronary heart disease (RR 






























Fig. 18.1 Radiotherapy process of care from the first evaluation to follow-up. (Modified from WHO World Alliance 
for Patient Safety Radiotherapy Safety Expert Consensus Group)
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for breast cancer was associated with cardiac 
absolute risk increase of 76.4 cases of coronary 
heart disease and 125.5 cases of cardiac death per 
100,000 person per year [32].
With regard to effects on the lungs, pneumo-
nia due to radiation occurs in 5.15% of patients 
undergoing radiation for mediastinal cancers as 
well as breast and lung cancers. The risk is 
directly associated with the volume of the irradi-
ated lung, intensity of radiations, fractionation 
and concurrent chemotherapy [30].
Toxicity of the digestive tract deriving from 
damage to the salivary glands is common in the 
radiation of the head-neck area, especially in the 
case of concurrent chemotherapy [33]. 
Esophagitis is also a common, early adverse 
effect whose frequency grows with increasing 
radioactive doses and in the presence of concur-
rent chemotherapy [34]. Acute enteritis after 
radiotherapy is usually a self-limiting process, 
mitigated by correcting the diet and administer-
ing anti-diarrheal medications. The main risk fac-
tors include the completion of chemotherapy 
before the radiation of the upper abdomen and 
the width of the irradiated areas. Patients at 
higher risk are those who receive total-body radi-
ations [35].
Acute bladder infection, including the most 
severe hemorrhagic cystitis, is a less common 
effect of radiotherapy, and the risk is elevated by 
concurrent chemotherapy [36].
Sexual dysfunctions, including impotence, are 
common after radiotherapy for cancers of the 
prostate and, to a lesser extent, the colon-rectum. 
It mainly concerns older patients, who exhibit a 
higher frequency of prostate cancer diagnosis. 
Erection dysfunction is more common with 
brachytherapy and with external radiotherapy 
[37]. In women, sexual dysfunctions are more 
common after radiotherapy for cervical and 
endometrial cancers. The adverse effects include 
a lower sex drive, vaginal dryness, and an overall 
sexual dissatisfaction [38].
Of no less importance is the role of RT in the 
multimodal treatment for many childhood 
tumors, offering an important opportunity when 
the limits of surgical possibilities have been 
reached. Due to growing tissue, children are par-
ticularly sensitive to radiation-induced adverse 
effects and the induction of secondary malignan-
cies [39]. The significant developments in radia-
tion therapy techniques together with risk-adapted 
treatment strategies have proven to offer advan-
tages for the treatment of children in limiting 
dose exposure. The basic principle of pediatric 
radiotherapy is to tailor treatment intensity 
according to the individual risk profile (Fig. 18.2).
Quality Assurance (QA) programs improve 
the effectiveness of RT programs. Indeed, QA in 
RT involves all the procedures that ensure consis-
tency of the dose/volume prescription, together 
with minimal dose to normal tissue and minimal 
exposure of the health operators [40].
Clinical, biological, and technical characteris-
tics, dose delivery, organizational and training 
aspects can all have an impact on the efficacy, 
safety, and risk of the treatment [41].
The reference model in literature for clinical 
risk management is “clinical governance.” It 





























Fig. 18.2 Risk-adapted RT in pediatric cancer patients. 
The process should take in account the host characteristic 
(children/adolescent), the tumor site and volume, the 
treatment planned (photons, protons, multimodality treat-
ment, etc.), the specific risk of organ dysfunction and 
finally the risk of secondary malignant neoplasm (SMN)
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nies that are aimed at building relationships 
between different components with clinical and 
organizational responsibilities, based on quality, 
safety, and continuous improvement.
Typically, errors include unauthorized acts, 
operative errors, equipment failures, initiating 
events, accident precursors, near-misses, and 
other mishaps [42]. The event can occur any-
where in the entirety of the patient’s clinical care 
process. Most of the errors are discovered in 
setup/treatment and during follow-up. There are 
still errors that are not covered by regular QA 
checks so individual clinics should perform a risk 
analysis of their own practice, classifying and 
learning from mistakes, to determine appropriate 
testing frequencies that maximize physicist time 
efficiency and patient treatment quality and to 
improve existing processes or implement new 
workflows [43]. The detection of errors is essen-
tial in the RT process as it minimizes the risk of 
repetition, activates mechanisms of correction, 
and instills in the staff a drive to improve the 
quality of daily activities.
The potential for errors in radiotherapy is high 
as it involves a complete patient pathway with 
many links in the chain. The interaction of many 
healthcare workers collaborating on highly tech-
nical measurements and calculations can in itself 
present a risk of error.
The United States Nuclear Regulatory 
Commission (NRC) maintains a large database 
of RT incidents and has estimated that about 60% 
or more of RT incidents are due to human error 
[44].
Beyond the rare cases in which there is inap-
propriate indication of treatment, there is still 
potential risk inherent to the treatment method. 
Three types of risk and consequent litigation 
exist: (1) correct RT treatment without the patient 
having given consent or being correctly informed 
of the risks and possible (potentially serious) side 
effects; (2) correct RT treatment not accompa-
nied by a satisfactory therapeutic response in 
terms of tumor control and OAR sparing; (3) 
incorrect RT treatment [20].
An example of the first type is the lack of ade-
quate explanation of fertility problems related to 
pelvic irradiation. Of the second type, possible, 
subjective biological factors or unrecognized 
variables can be considered; for example, the 
exclusive use of RT treatment instead of multi-
modality treatment is less justified in younger 
patients to limit and/or avoid serious, late side 
effects. The third case—incorrect RT treatment—
falls under malpractice due to inexperience, care-
lessness, or negligence. Such malpractice leads 
to civil and criminal liability where demonstrated 
and where there is definite cause of injury to the 
patient.
The WHO presents in “Radiotherapy Risk” a 
summary of all widely reported and major radio-
therapy incidents that led to significant adverse 
events for patients (such as radiation injury and 
death) and which have occurred in the last three 
decades (1976–2007) [41]. In total, 3125 patients 
were affected, of whom 38 patients (1.2%) were 
reported to have died due to radiation overdose 
toxicity. Overall, 55% of incidents occurred in 
the planning stage, while 45% occurred during 
the introduction of new systems and/or equip-
ment such as megavoltage machines.
The ROSIS database, a voluntary safety 
reporting system for Radiation Oncology for RT 
incidents in Europe [45] reports a total of 1074 
incidents between 2003 and 2008: 97.7% were 
related to external beam radiation treatment 
delivered with Linear Accelerator or Cobalt, and 
50% resulted in incorrect irradiation. Many inci-
dents arise during the pretreatment phase but 
only about 25% of the reported process-related 
incidents were detected prior to treatment. Of the 
cases in which an incident was not detected prior 
to treatment, an average of 22% of the prescribed 
treatment fractions were delivered incorrectly. 
The most commonly reported detection methods 
were “found at time of patient treatment” and 
during “chart-check.” The majority of the 
reported incidents (56%) were detected by 
 radiation therapists in the treatment unit. While 
the majority of incidents that are reported are of 
minor dosimetric consequence, on average they 
affect more than 20% of the patient’s treatment 
fractions.
Criteria for assessing treatment correctness are 
the following: (1) correspondence of the treatment 
schedule for administration of RT dose and techni-
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cal performance by the radiographer or portal 
images or CT on board (IGRT); (2) identification 
of the most restricted field of radiation possible, 
taking into account the assistance provided by 
modern diagnostic imaging devices in preparing 
the treatment plan and centering; (3) safety through 
quality control of the device and exactness of the 
dose delivered, which mainly falls under the com-
petence of the medical physicist.
The definition of organized protocols is funda-
mental; they should provide methods for the con-
stant monitoring of radiotherapy devices and 
identification of the person responsible for each 
process. To prevent any risk of incorrect calibra-
tion, devices should be submitted to quality con-
trol at the beginning of each new working cycle. 
Specific competence of the radiotherapist for the 
organ or system being treated has become 
accepted among the current criteria for treatment 
quality.
Due to rapidly increasing complexity during 
the last few years, comprehensive QA has become 
even more important for treatment planning soft-
ware, information handling, and treatment 
delivery.
The main health professionals involved in the 
delivery of RT are Radiotherapist Physicians, 
Radiation Therapists, and Medical Physicists, 
while the final guarantor of the process is the 
Radiotherapist Physician, who must acquire the 
patient’s informed consent, which is a process, 
not a form. The need to obtain informed consent 
for treatment is based on the patient’s right to 
self-determination and the fiduciary relationship 
between the patient and physician [46]. The 
Radiotherapist assumes responsibility for pro-
tecting the patient from errors and damage caused 
by the incorrect use of ionizing radiation (whether 
or not associated with drugs).
In the present era, RT is being enriched by big 
digital data and intensive technology. Modern 
radiotherapy departments transfer a great quan-
tity of data from diagnosis to planning and treat-
ment machines. The new technologies can help in 
reducing the risks but, when not used correctly or 
if the personnel is not adequately trained, can 
paradoxically act as a new source of error for 
manual procedures [47].
Multimodality image registration, intelligence- 
guided planning, real-time tracking, image- 
guided RT (IGRT), radiomics, and automatic 
follow-up surveys are the products of the digital 
era. Enormous amounts of digital data are created 
in the process of treatment, carrying both benefits 
and risks. Generally, decision-making in RT tries 
to balance these two aspects based on the archival 
and retrieving of data from various platforms.
Modern risk-based analyses show that many 
errors occurring in radiation oncology are due to 
failures in workflow [43, 48]. Medical imaging is 
crucial to RT; its application, referred to as IGRT, 
encompasses tumor diagnosis, staging, progno-
sis, treatment planning, radiation targeting, and 
follow-up care [49]. Setup errors, ranges of organ 
motion, and changes in tumor position and vol-
ume are most likely to be detected during an RT 
course with frequent imaging, which is becoming 
an essential requirement in order to attain the best 
local control of tumors and OAR sparing [50]. 
Various studies indicate that inconsistencies in 
anatomy contouring may be larger than errors in 
the other steps of the treatment planning and 
delivery process [51]. Some semiautomatic and 
automatic contouring methods have been pro-
posed, such as probabilistic atlases and machine- 
learning technologies, to minimize manual input 
and increase consistency in delineating clinical 
target volume (CTV) and planning target volume 
(PTV). Image guidance is suggested, allowing 
margin reduction to several millimeters and dose 
escalation while maintaining the sparing of the 
OAR. However, respiratory motion and artifacts 
may distort target volume. This can be compen-
sated for with the use of four-dimensional CT 
(4DCT) or instruments like “breath holding” that 
are able to facilitate the delivery of RT to a 
dynamic target rather than to a static volume. 
Tumor motion management has been a part of the 
IGRT effort and it markedly impacts radiation 
dose and volume of irradiated, normal tissue, as 
well as secondary cancer risk (SMN) [43].
The risks for RT-related SMN depend on the 
technique used (e.g., the risk for all tumors 
increases with the increase of number of fields, 
with higher energy, and with modulated/dynamic 
techniques) and vary in different organs and 
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tissues. Both size and shape of the PTV influence 
the risk of secondary malignancy. If we consider 
only SMN causing risk for life (e.g., sarcoma, 
carcinoma), they usually occur in healthy tissues 
near volumes irradiated with high-intermediate 
doses [52–55]. Of 30,000 adult patients treated 
between 1969 and 1989 with RT, 203 were re- 
admitted for RT due to an SMN. About 70% of 
SMNs occur in intermediate-high dose regions. 
The stomach, lungs, and colon are the most com-
mon sites for SMN after radiation exposure [54].
With the use of modern RT photon techniques 
such as intensity-modulated radiation therapy 
IMRT, the above-target, high dose volumes in 
healthy tissue have been drastically reduced com-
pared with conventional 2D- or 3D-RT.  One 
might expect a decrease in the number of sarco-
mas induced and (maybe with less certainty) a 
small decrease in the number of carcinomas. By 
contrast, the move from 3D-RT to IMRT involves 
more fields, and the dose–volume histograms 
show that as a consequence a larger volume of 
normal tissue is exposed to lower doses [56].
The greatest challenge in determining risk is 
that secondary cancers after RT have onset laten-
cies of 5–10  years for leukemia and about 
10–60  years for solid tumors after the initial 
treatment. Only longer term follow-up will allow 
a true assessment of the SMN risk. A risk-adapted 
strategy can be taken to optimize the routine fol-
low- up, the screening frequency, and the follow-
 up duration.
While IMRT marks the crowning achievement 
of photon-based external beam radiation therapy, 
the next step in improving physical-dose distribu-
tion naturally points to heavy-charged particle 
beams using the clinical application of Bragg 
peak. The recent introduction of particle therapy 
into clinical practice offers to minimize the radia-
tion dose to healthy tissues near cancer targets, 
offering significantly lower second cancer inci-
dence rates than photon-based therapy [53].
Problems related to the harmonious develop-
ment of RT in a growing multidisciplinary con-
text lie at the center of a growing interest to 
scientific groups. The scientific community of 
radiation oncologists is generally used to monitor 
the acute and late side effects related to treat-
ment, and consequently to adopt and to adapt 
methods from clinical Risk Management. The 
optimal use of preventative and integrated treat-
ment interventions based on a logical and sys-
tematic methodology is carried out through 
multiple, linked phases to improve the quality of 
health services and guarantee patient safety. Risk 
management is effective through the identifica-
tion, knowledge and analysis of risks and errors 
(via report systems, folder review, use of indica-
tors, etc.), identification and correction of causes 
(via Root Causes Analysis, Process Analysis, 
Failure Mode and Effect Analysis, etc.), monitor-
ing of preventive measures, and implementation 
and active support of proposed solutions.
Only integrated risk management can lead to 
changes in clinical practice and promote the 
growth of a healthcare culture that is more atten-
tive to patients and operators. It contributes indi-
rectly to the decrease in the cost of services and 
encourages the allocation of resources towards 
interventions aimed at developing safe and effi-
cient health organizations and structures.
18.7  Safety Practices 
and Implementation 
Strategy for Radiotherapy
Modern radiotherapy depends considerably on 
the transfer of patient data between different 
operative units, information systems, and staff of 
different disciplines.
The steps of the process are presented as fol-
lows in “Safety is No Accident—ASTRO” 
(American Society for Radiation Oncology, 
2019):
• Assessment of patient, or patient evaluation
• Radiation treatment preparation
• Clinical treatment planning
• Therapeutic simulation
• Dosimetric treatment planning
• Pretreatment quality assurance and plan 
verification
• Radiation treatment delivery
• Radiation treatment management
• Follow-up evaluation and care
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Care has to be taken at each step and general 
strategies are also needed to reach the theoretical 
goal of no accidents occurring.
One basic strategy for the improvement of 
safety in the radiotherapy process is the develop-
ment of a stable incident reporting and analysis 
structure. This could be designed in two steps. 
First, a systematic cross-check of the procedures 
should be established, at least at the end of the 
main subprocesses: clinical assessment and deci-
sion, target volume and organ at risk outlining, 
dosimetric treatment planning, and pretreatment 
checks. As a second step, it is important to instill 
in all operators the idea of error discovery and 
disclosure. This part of the process requires that 
all professionals (i.e., physicians, physicists, 
radiation therapists, etc.) are clearly informed 
about the potential advantages of a mandatory 
and tightened-up second check (i.e., a cross- 
check) of their actions, in order to create or main-
tain a no-blame culture within the department. To 
improve the global effectiveness of the check, 
every operator should be encouraged to record 
potential errors and report them within a well- 
structured reporting system or to dedicated 
professionals.
As stated by several authors, the quantitative 
and qualitative understanding of mistakes, gained 
by reporting, allows professionals to identify 
potential, necessary corrections to their organiza-
tion or its processes, or to the technology avail-
able, in order to prevent future incidents.
If no incidents are known, that is, if operators 
do not report problems, no improvement will be 
possible.
18.8  Volumes–Outcomes 
Relationship in Surgery
Patient safety in oncology should also be consid-
ered from the perspective of the outcomes associ-
ated with complex surgical activities or the 
procedures that comprise a broader therapeutic 
approach, in order to find a significant applica-
tion to solid tumors. The risk for cancer patients 
undergoing surgical procedures are linked, in the 
first place, to the generic risks that are typical of 
each surgical procedure, such as infection, selec-
tion of the wrong site, etc.; however, this section 
discusses only the risks associated with outcomes 
such as complications, hospitalization within 
30 days from surgery, or death for surgery per-
formed in specialized surgery centers, which dif-
fer by number of performed surgeries.
Since the earliest observations published 
about a century ago [57], a vast amount of studies 
have come to the conclusion that higher volume 
correlates to better outcomes in a number of med-
ical and surgical procedures, especially in high- 
risk surgery. The relation between workload and 
the latter was regarded as a key factor in the 
regionalization of healthcare providers, particu-
larly those offering surgery with a higher tech-
nology content [58]. For an overview of the 
medical and surgical specialties for which vol-
umes–outcomes relationship has been found, 
three recent works [59–61] are available in litera-
ture. The latest report [59] highlighted for surgi-
cal procedures in oncology a positive association 
of considered outcomes with a high hospital vol-
ume for 14 out of 18 studied conditions (i.e., can-
cers of the colon, colon-rectum, esophagus, 
breast, ovaries, pancreas, lung, prostate, kidney, 
bladder, and head and neck), while for other sur-
gical procedures no sufficient evidence was 
found to evaluate the association (i.e., for testis, 
brain, and pediatric cancers).
Workload volume thus acts as a proxy mea-
sure for various processes and provides charac-
teristics that in turn may directly influence 
outcomes. The causes of this association have 
been investigated since the first statistical evi-
dence of an association with mortality [62]. It has 
been hypothesized that for high-risk surgical 
 procedures with relatively short lengths of stay 
the relationship could be largely explained by 
surgeon volume. A systematic review recently 
investigated whether high-volume surgeons of 
various surgical specialties perform better surger-
ies, (i.e., the surgeon’s volume–outcome relation-
ship) [61]. A positive volume–outcome 
relationship is apparent for most procedures/con-
ditions (e.g., colorectal cancer, bariatric surgery, 
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and breast cancer) and can be related to the 
“learning curve” of a surgeon. The simple concept 
of “learning by doing” and the idea that “practice 
makes perfect” are often used to exemplify this 
notion. A drawback of this work is that these 
results are partly based on systematic reviews 
with methodological weaknesses, in particular 
the possible risk of bias in the primary studies. 
On the other hand, the hospital volume–outcome 
relationship has been investigated, as in one 
recent, German work [63]. Policy makers need 
good evidence for policy making around the stan-
dardization of surgical procedures. For proce-
dures requiring an extended length of stay, 
intensive care unit admission, and/or multidisci-
plinary inpatient or outpatient care (i.e., 
esophagectomy, pneumonectomy, hepatobiliary 
resection), the relationship can be largely 
explained by hospital volume, due to a large mul-
tidisciplinary team and many hospital processes 
of care required to achieve high-quality care.
Drawing parallels between the “experience 
curve” describing a decline in unit costs as func-
tion of cumulative production experience, a rela-
tion well documented in industrial economics, 
the Author underlines that a substantial number 
of deaths could be averted if all patients were 
treated in hospital having results similar to those 
of high-volume hospitals. Such consideration 
would represent a strong support in favor of 
regionalizing certain surgical procedures. To 
make a long story short: larger volumes lead to 
better outcomes. At a more fundamental level, 
one may ask whether a model focusing on vol-
umes may be appropriate. Many questions arise 
concerning the relationship between outcomes 
and experience accumulated over several years, 
the significance of the procedure alone compared 
with the more general set of procedures to which 
a specific procedure belongs to. Moreover, it 
should be clarified whether to regionalize opera-
tions into larger medical centers even when 
smaller hospitals with high volumes of specific 
procedures exists. This perspective raises some 
issues with medical students and young physi-
cians learning curve. In summary, volume alone 
probably does not automatically result in better 
performance, but acts as a proxy measure for 
various processes and provides characteristics 
that in turn may directly influence outcomes.
In a large national dataset of Medicare 
patients, it was found that, after more than three 
decades, both absolute and relative differences in 
adjusted mortality persist between hospitals with 
the lowest and highest volume [64]. Two recent 
overviews of systematic reviews [61, 63] found 
evidence synthesis based on systematic reviews 
instead of primary studies. This result supports a 
positive volume–outcome association for the sur-
geon/practitioner performing most procedures/
conditions. However, results are partly based on 
systematic reviews with methodological weak-
nesses, as to say the lack of consideration of the 
risk of bias in the primary studies [61]. The 
authors suggest that forthcoming reviews, to 
compare better findings across studies, should 
pay more attention to methodology specific to 
volume–outcome relationship.
A recent systematic review and meta-analysis 
on volume–outcome associations in head and 
neck oncology identified six studies that assessed 
long-term survival with conflicting results of lim-
ited external validity [65]. Of the studies ana-
lyzed, only one was able to assess both hospital 
and surgeon volume concurrently. This is a sig-
nificant limitation because it has been previously 
demonstrated that, depending on the procedure, 
either surgeon or hospital volume can explain 
most of the effect on outcome. Thus, these studies 
cannot delineate between the relative importance 
of hospital- and surgeon-volume effects [65].
Considering head and neck cancer patients, 
the same authors took into account data coming 
from a single payer national healthcare system. 
The results of the meta-analysis were consistent 
with the hypothesis: for head and neck cancer 
resections that often require an extended hospital 
stay and inpatient and outpatient multidisci-
plinary care delivered by a large team, the rela-
tionship appears to be explained not only by 
surgeon volume but more strongly by hospital 
volume [66].
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18.9  Case History
 1. A 55-year-old woman with a recent diagnosis 
of early-stage triple negative breast cancer 
was admitted to the breast unit of a National 
Cancer Center to receive the second cycle of a 
regimen with epirubicin and cyclophospha-
mide. Although an apparently correct order 
was written by the physician, and the pharma-
cist entered the right dose of both drugs 
through the computerized provider order entry 
system, 7 days after the treatment administra-
tion the patient experienced a severe toxicity 
(i.e., febrile neutropenia and G3 stomatitis). 
Therefore, a deep verification process was 
started in order to exclude potential medica-
tion errors responsible for the observed side 
effects. In particular, a rigorous examination 
of the medical record together with the analy-
sis of the various steps of the therapeutic 
course were performed. Notably, the second 
pharmacist, who was charged with indepen-
dently verify the computerized order, signed 
the drug preparation as correct. In turn, before 
treatment administration, two nurses were 
charged to appropriately check for the phar-
macists’ signatures, and to independently 
compare the dose on the medication to the 
written physician order. Both nurses con-
firmed the correctness of the process, and the 
drug administration was initiated. 
Subsequently, before all of the medication had 
infused and according on standard proce-
dures, the dose on the medication bag was 
compared to the written order, but no errors 
were found. Appropriately, every step about 
treatment prescription, preparation, and 
administration were adequately reported on 
the medical chart. This approach allowed us to 
recapitulate the whole event and to identify 
the error that had consisted into a wrong pro-
gramming of the interval between the two 
cycles of therapy, administered at a distance 
of 2 weeks instead of 3. Therefore, the patient 
received an unintentional dose-dense regimen 
without support of pegfilgrastim. The physi-
cian was misled by the normal values of the 
blood count before starting the second cycle 
of chemotherapy. This is a clear example of an 
error due to a failure of a CPOE system to pro-
vide a proper alert about the wrong interval 
between two cycles of treatment, and it under-
lines the importance of a correct set of proto-
cols with each distinct variable unequivocally 
detailed.
 2. Patient undergoing two subsequent treatments 
with tomotherapy on two different areas of the 
same anatomical site. For the two treatments, 
two different immobilization and positioning 
masks were made with different positioning 
points. The IGRT (Image-Guided Radiation 
Therapy) procedure, mandatory before each 
treatment, requires the acquisition of images 
with the patient wearing the mask, positioned 
on the treatment bed, and a comparison of the 
acquired images with the simulation images, 
on which the dosimetry plan was conducted. 
For this patient, the IGRT procedure indicated 
an anomaly of a few centimeters along the 
cranial-caudal direction and a different rota-
tion of the patient body on the transversal 
plan. The repositioning needed to return to the 
correct anatomical reference point was inter-
preted as a positioning error of the LASER 
during the planning phase. In addition, no 
investigation was conducted on the different 
rotation of the patient’s body on the transver-
sal plan. The repositioning according to the 
IGRT procedure movements was conducted 
and the patient received therapy in three ses-
sions. After the third session, an evaluation of 
the images revealed that the positioning pre- 
IGRT did not coincide with that of the simula-
tion and that the repositioning post-IGRT did 
not guarantee the precision required in these 
cases. The treatment was suspended, and an 
investigation indicated that the immobiliza-
tion and positioning mask of the first treat-
ment had not been destroyed as by requirement, 
and that at the first three sessions of the sec-
ond treatment, the patient had been immobi-
lized and positioned using the same mask of 
the first treatment. The second treatment was 
modified, in consideration of what had 
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happened during the first three sessions, and 
the patient continued therapy with the new 
treatment and the correct mask for the subse-
quent sessions without adverse effects.
18.10  Final Recommendations
Implementation of best practices in clinical 
oncology, to reduce the risk of error and pre-
venting harm to the patient, must be seen as a 
priority among professionals and health organi-
zations. The growing complexities of modern 
medicine require continuous updates and 
adjustments to meet new necessities. The safest 
possible administration of chemotherapy drugs 
requires a continuous surveillance of the meth-
ods through which the drugs are administered. 
The implementation of an orderly method of 
administration of the drugs is, today, a manda-
tory process of revision, if we want to obtain a 
significant reduction in the risk of error that can 
result in harm to the patient. The preparation of 
cytotoxic drugs can often lead to error. 
Therefore, it should be centrally managed in 
the hospitals and possibly guaranteed by dedi-
cated technicians and pharmacists. The proce-
dures not only must be kept in writing and 
shared with the team, but they also need to be 
monitored and revised in order to avoid the 
introduction of new types of errors. They can 
take advantage of integrated electronic systems, 
such as Computerized Provider Order Entry 
(CPOE) and Clinical Decision Support System 
(CDSS). Each hospital where oncology prac-
tices are provided must have a pharmacy staff 
trained to guarantee the appropriate preparation 
of drugs, which can also benefit from new tech-
nologies that include always improving moni-
toring systems and bar coding. The organization 
must enforce a safety culture among the hospi-
tal staff members, so that they can feel compe-
tent and involved in the processes of improving 
quality of services and preventing pharmaco-
logical errors. Patients should be encouraged to 
contribute to their own care through patient 
education programs with focus on self-evalua-
tion and on monitoring the effect of their treat-
ments. Efforts must be made with the aim of 
improving systems to report and analyze errors. 
Coherently, strong strategies must be intro-
duced to promote inter- professional and 
patient–provider communication.
Concerning radiotherapy, it is necessary: to 
document in detail the different phases of the 
process; to be able to rely on adequate informa-
tion systems; to work in team; to support and 
implement a culture of safety training; to incre-
ment a system of error reporting and near-misses; 
to start methods of error analysis; to support con-
tinuous education and training, especially in case 
of introduction of new technologies.
In conclusion, there should be an open com-
munication among the different professionals 
involved in management of treatment with the 
aim to take inspiration from the best practices, 
which must be defined on the basis of scientific 
evidence. Moreover, the Hospital Organization 
must ensure a peaceful environment and a serene 
atmosphere, warranting necessary organizational 
conditions.
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